API
< Back to all clusters
[HEALTH] · India · 2 sources

started · updated

India to reduce prices of 137 cancer medicines by up to 70%

India is set to reduce the prices of 137 non-scheduled anti-cancer medicines by up to 70% starting November 9, 2026. The National Pharmaceutical Pricing Authority (NPPA) has implemented this measure by capping trade margins at 30% of the maximum retail price (MRP).

The regulation covers immunotherapy and other treatments for more than 20 types of cancer, including breast, prostate, colon, ovarian, and cervical cancers. Specific drugs identified for price reductions include Pembrolizumab, Durvalumab, Osimertinib, Bevacizumab, Denosumab, and Pegfilgrastim.

This initiative follows a 2019 government action that capped margins on 42 drugs, which led to price drops of up to 90% for 526 brands. To ensure stability, authorities have instructed manufacturers to maintain current production and supply levels to prevent potential shortages during the transition.

Entities

India · Ministry of Chemicals and Fertilizers · National Pharmaceutical Pricing Authority

Sources